Difluoromethylornithine (DFMO) is an early clinically used cancer treatment drug that inhibits the activity of ornithine decarboxylase (ODC), reducing the biosynthesis of polyamines within cancer cells and thereby inhibiting their proliferation. The gene discussed is ODC1; the disease is cancer.